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Abstract: In Phenylketonuria (PKU), the peptide structure of the protein substitute (PS),
casein glycomacropeptide (CGMP), is supplemented with amino acids (CGMP-AA). CGMP may
slow the rate of amino acid (AA) absorption compared with traditional phenylalanine-free amino
acids (Phe-free AA), which may improve nitrogen utilization, decrease urea production, and alter
insulin response. Aim: In children with PKU, to compare pre and postprandial AA concentrations
when taking one of three PS’s: Phe-free AA, CGMP-AA 1 or 2. Methods: 43 children (24 boys,
19 girls), median age 9 years (range 5–16 years) were studied; 11 took CGMP-AA1, 18 CGMP-AA2,
and 14 Phe-free AA. Early morning fasting pre and 2 h postprandial blood samples were collected
for quantitative AA on one occasion. A breakfast with allocated 20 g protein equivalent from PS
was given post fasting blood sample. Results: There was a significant increase in postprandial AA
for all individual AAs with all three PS. Postprandial AA histidine (p < 0.001), leucine (p < 0.001),
and tyrosine (p < 0.001) were higher in CGMP-AA2 than CGMP-AA1, and leucine (p < 0.001), threonine
(p < 0.001), and tyrosine (p = 0.003) higher in GCMP-AA2 than Phe-free AA. This was reflective of the
AA composition of the three different PS’s. Conclusions: In PKU, the AA composition of CGMP-AA
influences 2 h postprandial AA composition, suggesting that a PS derived from CGMP-AA may be
absorbed similarly to Phe-free AA, but this requires further investigation.
Keywords: phenylketonuria; PKU; glycomacropeptide; amino acid; absorption
1. Introduction
Protein substitutes are an essential source of synthetic protein in the dietary treatment of classical
phenylketonuria (PKU). Protein is the second major constituent in the body, critical for growth and
supporting a wide range of metabolic and cellular functions. Amino acids (AA) are engaged in
a dynamic process of protein synthesis and degradation. In PKU, it is critical that the AA profile of
protein substitutes are carefully developed, with a balance of AAs that meet WHO 2007 [1] minimal
AA requirements [2,3]. Furthermore, there is evidence that modification of the large neutral amino
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acid (LNAA) profile (including tyrosine, leucine, isoleucine, methionine, valine, histidine, threonine
and tryptophan) will enhance brain AA concentrations. In mice fed LNAA, an improvement in
brain neurophysiology with increased brain serotonin and norepinephrine, and lower phenylalanine
concentrations was observed [4]. It is also important that the composition and protein source of protein
substitutes help support physiological AA absorption [5].
In PKU, protein substitutes are either manufactured using artificial AA without phenylalanine or
based on caseinglycomacropeptide (CGMP), a by-product of the cheese making process [6]. Artificial AAs
are generated from plant-based materials converted into sugars, fermented, and purified [7]. In contrast,
CGMP modified for use in PKU is a mix of bioactive glycopeptides containing residual phenylalanine
with the addition of essential and semi essential artificial AAs (CGMP-AA). Some authors [8,9] describe
CGMP as an intact protein. However, proteins are large macromolecules made up of one or more
polypeptide chains, whereas CGMP is a 64 macropeptide and therefore classification as an intact protein
source is a misrepresentation [10]. Although there is knowledge about the absorption of AAs and intact
protein, little is known about the absorption properties of CGMP-AA.
It is well recognized that the kinetic and biochemical properties of natural proteins change
depending on the quality of protein, which is determined by its AA pattern, the speed of digestion,
absorption and release of AAs into the circulation [11]. Protein metabolism has been extensively
studied [12,13]. It is established that whey protein is rapidly absorbed, and the release of some
individual AAs (leucine, isoleucine) influences anabolic and hormonal pathways [11,14,15]. In contrast,
the appearance of plasma AAs following a meal with casein is slower, with protein synthesis increased
and breakdown inhibited [11,16,17]. AAs are directly available for absorption by the small intestine,
and so are quickly absorbed, potentially resulting in their transient imbalance, and altering their
bioavailability. AA antagonism, the presence of high concentrations of specific AAs, may alter the AA
equilibrium, impairing the absorption of other AAs and limiting absorption and metabolism [18]
In PKU, several authors [19–22] have demonstrated improved utilization of AAs when protein
substitutes are taken in divided doses throughout the day. However, this still does not produce
a normal physiological response; protein substitutes are usually taken as an addition and not as
an integral part of a meal. In an animal study, the metabolic and biological influences of CGMP were
compared with Phe-free AA, with CGMP giving a more physiological response decreasing metabolic
stress and immunity [23]. In subjects with PKU, van Calcar et al. [24] suggested CGMP improved
protein synthesis and nitrogen retention compared to Phe-free AA. However, peptides may be absorbed
more rapidly than AA [14,25], thereby questioning the rate of delivery of AAs from CGMP-AA.
In this pilot, parallel study in children with PKU, we aimed to investigate if there were any
differences following an overnight fast in the pre and postprandial AA absorption after taking one
breakfast dose of Phe-free AA compared with two different CGMP-AA formulations with varying
AA compositions.
2. Ethical Permission
The South Birmingham Research Ethics committee granted a favorable ethical opinion. The study
was registered 13/WM/0435 IRAS (integrated research application system) 129497. Written informed
consent was obtained for all subjects from at least one caregiver with parental responsibility and
written assent obtained from the subject if appropriate for their age and level of understanding.
3. Materials and Methods
3.1. Inclusion Criteria
Entry into the study included: children diagnosed with PKU by newborn screening, aged 5–16 years
and treated with diet only. Children had to be adherent with diet and protein substitute intake, with 70%
of routine blood phenylalanine concentrations within European PKU Guideline target range [26] for
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six months before study enrolment. Target blood phenylalanine ranges were 120 to 360 µmol/L for
children aged 5 up to 12 years and 120 to 600 µmol/L for 12 years and older [26].
3.2. Study Design
Pre and postprandial AA absorption was measured on one occasion after six months of taking
either Phe-free AA, or one of two CGMP formulations (CGM-AA1 or CGMP-AA2). Children attended
the hospital after an overnight fast (minimal fasting time 10 h). CGMP-AA1 had been taken for
six months by 11 children as part of a pilot study the results have previously been published [27].
Following the results of the pilot study, a further 18 children were recruited and took CGMP-AA2,
which was a modification of CGMP-AA1. Nineteen children remained on Phe-free AA. All children
had fasting capillary finger pricks (0.5 mL), for quantitative plasma AAs. Children then took 20 g
protein equivalent from Phe-free AA, CGMP-AA1 or CGMP-AA2, followed by a breakfast providing
less than one third of their phenylalanine/natural protein allowance (median 2 g natural protein (100 mg
phenylalanine), range 1–6). After 120 min post protein substitute and breakfast, a second capillary
sample was taken for AAs.
3.3. Protein Substitutes (PHE-FREE AA and CGMP1, CGMP2)
The AA profile and nutritional composition of the three different protein substitutes (provided by
Vitaflo International) are given in Table 1. All the children in the Phe-free AA group took the same
liquid pouch (PKU Cooler 20). For each 20 g protein equivalent, Phe-free AA provided 124 kcal, 9.4 g
carbohydrate, and 0.7 g fat, and CGMP-AA1 and CGMP-AA2, 120 kcal, 6.5 g carbohydrate, and 1.5 g fat.
CGMP-AA2 had increased amounts of tyrosine, leucine, histidine, and tryptophan, and less methionine,
lysine, glycine, and aspartic acid than CGMP-AA1. Except for threonine (higher in CGMP-AA1 and
2), glycine and methionine (higher in CGMP-AA1), and leucine (higher in CGMP-AA2), all the other
AAs were slightly but not significantly higher in the Phe-free AA. Glutamine was naturally present
in CGMP-AA, but not added to Phe-free AA. The energy content of the three products was similar,
although the carbohydrate content was 30% higher in the Phe-free AA, and fat content 53% higher in
the two CGMP-AA products, but overall fat intake was low from all three protein substitutes.
The single dose of Phe-free AA, CGMP-AA1, and CGMP-AA2 given in this study provided 20 g
protein equivalent. The CGMP-AA1 and CGMP-AA2 also provided an additional 36 mg phenylalanine
for each 20 g protein equivalent. The children chose either Phe-free AA or CGMP-AA, depending on
their taste preference.
Table 1. Nutritional composition of CGMP-AA 1, CGMP-AA2, and PHE-FREE AA protein substitutes.
Protein Substitute CGMP-AA1 CGMP-AA2 PHE-FREE AA
Nutrients Units Per 20 g PE Sachet Per 20 g PE Sachet Per 20 g PE Pouch
Calories Kcal 120 120 124
Protein equivalent g 20 20 20
Total Carbohydrate g 6.5 6.5 9.4
Sugars g 2.2 2.2 7.8
Total Fat g 1.5 1.5 0.7
Docosahexaenoic Acid mg 84 84 134
Arachidonic Acid mg - - -
Fiber g 0.1 0.1 -
Comprehensive amino acid profile
L-amino acids CGMP-AA1 CGMP-AA2 PHE-FREE AA
20 g PE 20 g PE 20 g PE
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Table 1. Cont.
L-Alanine g 0.76 0.83 0.92
L-Arginine g 1.00 0.96 1.5
L-Aspartic Acid g 2.04 1.31 2.37
L-Cystine g 0.01 0.24 0.61
L-Glutamine g 2.49 2.70 -
Glycine g 2.77 1.20 2.35
L-Histidine g 0.42 0.70 0.92
L-Isoleucine g 1.37 1.35 1.62
L-Leucine g 1.30 3.00 2.54
L-Lysine g 1.07 0.80 1.67
L-Methionine g 0.54 0.28 0.45
L-Phenylalanine g 0.03 0.03 -
L-Proline g 1.51 1.52 1.69
L-Serine g 0.98 0.96 1.04
L-Threonine g 2.17 2.20 1.62
L-Tryptophan g 0.17 0.40 0.5
L-Tyrosine g 1.01 2.24 2.38
Taurine g - - 0.04
L-Valine g 1.13 1.09 1.86
CGMP-AA 1/CGMP-AA 2: casein glycomacropeptide formula 1 and 2; PHE-FREE AA: Phenylalanine-free L-amino
acid (PKU Cooler 20, Vitaflo International).
3.4. Measurement of Quantitative Plasma Amino Acids
Capillary blood samples were collected into a Sarstedt tube and analyzed by ion exchange HPLC
with postcolumn derivatization and spectrophotometric detection (Biochrom, Harvard Bioscience,
Holliston, MA, USA). Prior to analysis, separated lithium-heparinized plasma was deproteinized 1:1
with 8% sulphosalicylic acid containing an internal standard, S-2-amino-ethyl-L-cysteine hydrochloride
(Sigma, Merck, St. Louis, MO, USA). Quantitative amino acids (QAA) were analyzed except tryptophan
and asparagine, which are not reported by our laboratory. Nonproteinogenic AA ornithine, citrulline,
and taurine were included in the analysis. The individual pre- and postprandial AAs were quantitated
(QAA) and the total AAs, total large neutral amino acids (LNAA), total essential amino acids (EAA),
and total branched chain amino acids (BCAA) were calculated from these results. We report total AAs,
LNAAs, BCAA, and EAAs, together with individual AAs.
3.5. Statistics
Descriptive statistics are reported as medians with associated interquartile ranges. Differences in
AAs at baseline and follow-up are assessed using a paired t-test. Differences between the three
treatment groups are performed using linear regression with differences at follow-up adjusting for
baseline covariate values. All analyses are performed in the statistical package R (Version 3.3).
4. Results
4.1. Subjects
Forty-three (41 European and 2 Asian origin) children with PKU, with a median age of 9 years
(range 5–16) were recruited and participated in the study. The number of children in each group was:
Phe-free AA, n = 14 (8 boys and 6 girls), CGMP-AA1, n = 11 (5 boys and 6 girls), and CGMP-AA2,
n = 18 (11 boys and 7 girls). The median age (range) in the groups were: CGMP-AA1, 8.3 years (6–16),
CGMP-AA2, 8.4 years (5–14) and Phe-free AA, 12.9 years (5–15). There was significant difference in age
between CGMP-AA2 and the Phe-free AA group (p = 0.001). The median phenylalanine concentration
for 12 months pre-study (all the children were taking Phe-free-AA) was 288 µmol/L (140–600).
In all three groups, the median daily dose of protein equivalent from protein substitute was
60 g/day (range 40–80 g), and the median amount of prescribed natural protein was 5.5 g/day (range
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3–30 g) or 275 mg phenylalanine (range 150–1500 mg). The majority had classical PKU, except two
children who were mild according to their untreated blood phenylalanine levels at diagnosis and
dietary phenylalanine tolerance.
4.2. Quantitative Plasma Amino Acid Results
Individual Amino Acids
Significant pre and postprandial differences for most individual AA were observed within each
group (Table 2).
Preprandial valine was significantly lower with CGMP-AA2 than CGMP-AA1 (p = 0.031) and
CGMP-AA2 vs. Phe-free AA (p < 0.001). For CGMP-AA1 vs. Phe-free AA, there were no significant
preprandial changes.
Postprandial CGMP-AA1 vs. CGMP-AA2: histidine (p < 0.001), leucine (p < 0.001) and tyrosine
(p < 0.001) were significantly higher for CGMP-AA2, while methionine (p < 0.001) significantly lower
compared with CGMP-AA1.
Postprandial CGMP-AA1 vs. Phe-free AA: histidine (p = 0.005) and tyrosine (p = 0.005) were
significantly higher in Phe-free AA, but isoleucine (p = 0.008), methionine (p < 0.001), threonine
(p = 0.001) significantly lower. For CGMP-AA2 v Phe-free AA, leucine (p < 0.001), threonine (p < 0.001),
and tyrosine (p = 0.003) were all significantly higher in CGMP-AA2.
Changes in the pre and postprandial AA concentrations between the groups appeared to be
mainly a reflection of the different amino acid compositions of the three protein substitutes, being most
evident between CGMP-AA1 and CGMP-AA2. CGMP-AA2 had higher amounts of histidine, leucine,
and tyrosine, and lower methionine and valine compared to CGMP-AA1.
4.3. Total Amino Acids, LNAA, BCAA, and EAA
There were similar significant pre and postprandial changes within the groups for total AAs,
LNAA, BCAA and EAA (Table 3(a–d), Figure 1a–d). No significant pre or postprandial changes were
observed between any of the three groups when comparing total AA, LNAA, BCAA, or EAAs.
Nutrients 2020, 12, 2443 6 of 13


































ˆ 0.007, ˆˆ <0.0001, ˆˆˆ <0.002





















































ˆ 0.02, ˆˆ 0.001












ˆ 0.001, ˆˆ 0.001
TT 0.035






















ˆ 0.003, ˆˆ <0.0001, ˆˆˆ 0.004












ˆˆ <0.0001, ˆˆˆ 0.003

























ˆ 0.001, ˆˆ <0.0001, ˆˆˆ 0.0001

























ˆ 0.001, ˆˆ <0.0001, ˆˆˆ 0.002











(51–141) ˆ 0.004, ˆˆ 0.0004, ˆˆˆ 0.004




































































ˆ 0.002, ˆˆ <0.0001, ˆˆˆ 0.0001












ˆ 0.002, ˆˆ <0.0001, ˆˆˆ 0.0001














ˆ 0.002, ˆˆ <0.0001,ˆˆˆ 0.0001
T 0.031, § <0.001
Key: ˆ, ˆˆ, ˆˆˆ significant differences within CGMP1,2 and Phe-free AA. Preprandial changes: T = CGMP1 v2, § = CGMP2 vPhe-free AA. Postprandial changes TT = CGMP1v2, ** = GGMP1
vs. Phe-free AA, §§ = CGMP2 vs. Phe free AA. p = significant value
Nutrients 2020, 12, 2443 8 of 13
Table 3. (a) Median pre and postprandial total amino acids results for CGMP-AA1, CGMP-AA2, and PHE-FREE AA protein substitutes. (b) Median pre and
postprandial EAA for CGMP-AA1, CGMP-AA2, and PHE-FREE AA protein substitutes. (c) Median pre and postprandial BCAA for CGMP-AA1, CGMP-AA2,
and PHE-FREE AA protein substitutes. (d) Median pre and postprandial LNAA for CGMP-AA1, CGMP-AA2, and PHE-FREE AA protein substitutes.
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CGMP-AA 1, CGMP-AA 2: caseinglycomacropeptide formula 1 and 2, PHE-FREE AA: Phenylalanine-free L-amino acids.*, **, *** p = significant value, ns not significant.
Nutrients 2020, 12, 2443 9 of 13






Figure 1 (a) Total median pre and postprandial amino acid concentrations for total amino acids (n = 
17) for CGMP-AA1, CGMP-AA2, and PHE-FREE AA protein substitutes. (b). Total median pre and 
postprandial amino acid concentrations for EAA (n = 7) for CGMP-AA1, CGMP-AA 2, and PHE-FREE 
AA protein substitutes. (c) Total median pre and postprandial amino acid concentrations for BCAA 
(n = 3) for CGMP-AA1, CGMP-AA2, and PHE-FREE AA protein substitutes. (d) Total median pre and 
postprandial amino acid concentrations for LNAA (n = 8) for CGMP-AA1, CGMP-AA2, and PHE-
FREE AA protein substitutes. 
5. Discussion 
This pilot study showed that that the postprandial AA concentrations largely reflected the AA 
profile of each of the protein substitutes used. CGMP-AA2 contained higher amounts of tyrosine, 
histidine, and leucine, and lower amounts of methionine and valine compared to CGMP-AA1. These 
changes were mirrored in the higher postprandial peaks of tyrosine, histidine, and leucine observed 
between CGMP-AA1 vs. CGMP-AA2. Although there was no postprandial change between the 
groups for valine, preprandial levels were lower between CGMP-AA1 vs. CGMP-AA2 and CGMP-
AA2 vs. Phe-free AA. This is not easily explained physiologically, but may reflect a chance finding, 
or changes as a result of the competition between the AAs. 
It is interesting to speculate on the postprandial changes, as it seems the more AA added to the 
protein substitute, the higher the AA concentrations were when measured at 120 min. The 
physiological consequence of these higher AAs is unknown. Postprandial tyrosine was significantly 
higher in CGMP-AA2 compared with CGMP-AA1 as a direct response of adding extra tyrosine. 
Norepinephrine is derived from tyrosine and is a principal brain neurotransmitter and so the 
provision of adequate tyrosine is essential to produce this monaminergic neurotransmitter, which is 
of clinical significance. Ney et al. [28] measured fasting tyrosine and tryptophan concentrations in 
subjects taking Phe-free AA compared to CGMP-AA and found their concentrations were 50% higher 
with Phe-free AA. Gut serotonin levels and microbiome-derived compounds made from tyrosine and 
tryptophan, although not significantly different, were higher in the CGMP-AA group, suggesting an 
improved bioavailability of tyrosine and tryptophan [29]. 
i . (a) T tal and postprandial amino acid concentrations for total mino acids (n = 17)
for CGMP-AA1, CGMP-AA2, and PHE-FREE A protein substitutes. (b).
7) for CG P- 1, - 2, a P E-
i it t s. (c) t l i i l i tr ti s f r
3) for CGMP-AA1, CG P- 2, and P E-F pr tei s stit t . (d) T t l e i r
ino acid concentrations for LNA (n = 8) for CGMP-AA1, CGMP-AA2, and PHE-FR E
AA protein substit te .
5. Discussion
This pilot study showed that that the postprandial AA concentrations largely reflected the AA
profile of each of the protein substitutes used. CGMP-AA2 contained higher amounts of tyrosine,
histidine, and leucine, and lower amounts of methionine and valine compared to CGMP-AA1.
These changes were mirrored in the higher postprandial peaks of tyrosine, histidine, and leucine
observed between CGMP-AA1 vs. CGMP-AA2. Although there was no postprandial change between
the groups for valine, preprandial levels were lower between CGMP-AA1 vs. CGMP-AA2 and
CGMP-AA2 vs. Phe-free AA. This is not easily explained physiologically, but may reflect a chance
finding, or changes as a result of the competition between the AAs.
It is interesting to speculate on the postprandial changes, as it seems the more AA added to the
protein substitute, the higher the AA concentrations were when measured at 120 min. The physiological
consequence of these higher AAs is unknown. Postprandial tyrosine was significantly higher in
CGMP-AA2 compared with CGMP-AA1 as a direct response of adding extra tyrosine. Norepinephrine
is derived from tyrosine and is a principal brain neurotransmitter and so the provision of adequate
tyrosine is essential to produce this monaminergic neurotransmitter, which is of clinical significance.
Ney et al. [28] measured fasting tyrosine and tryptophan concentrations in subjects taking Phe-free
AA compared to CGMP-AA and found their concentrations were 50% higher with Phe-free AA.
Gut serotonin levels and microbiome-derived compounds made from tyrosine and tryptophan,
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although not significantly different, were higher in the CGMP-AA group, suggesting an improved
bioavailability of tyrosine and tryptophan [29].
In our study, although individual AAs changed significantly within groups, no significant
differences were observed between groups for total AAs, LNAAs, BCAAs, and EAAs. After 120 min,
AA concentrations had increased significantly above fasting levels with a 56% increase in CGMP-AA1,
73% increase in CGMP-AA2 and a 42% increase in the Phe-free AA group. The total AA concentration
per 20 g protein equivalent for CGMP-AA1 was 21 g, CGMP-AA2, 22 g, and Phe-free AA 24 g. It seems
unlikely that the peptide-based CGMP-AA offered any advantage in minimizing the kinetic release of
AA, although postprandial bloods were not measured in the first hour post consumption.
This exploratory investigation was a crude assessment to explore if there were any kinetic
differences between AAs and a peptide based CGMP-AA with a different AA profile. In a crossover
study in eleven adults with PKU, MacLeod et al. [30] measured postprandial AAs after 180 min
following a breakfast with Phe-free AA or CGMP-AA. CGMP-AA was consumed as GMP foods
rather than drinks. In the CGMP-AA group, postprandial threonine and isoleucine were significantly
higher, and total AA concentrations just reached a significant difference compared to the Phe-free AA
group. The authors suggested that based on the higher concentrations of insulin and total plasma
AAs in the GMP group, CGMP-AA had an improved AA absorption profile compared to Phe-free
AA. Although the preprandial breakfast was isocaloric, the AA composition of both products was
not stated and the protein substitute in the form of a food versus a liquid may alter the absorption of
AAs. Similarly, a non-physiological response causing a rapid rise in insulin concentrations may not be
ideal. What remains unknown both in this and our own study is at what point maximum and nadir
concentrations for AAs were reached, and neither study measured concentrations over 240 min or
used a whole protein source as a comparison from which maximum and minimum AA concentrations
could be compared.
Ahring et al. [31] compared two groups of protein substitutes: group 1, CGMP only versus Phe-free
AA (different protein sources but the same AA composition) and group 2, CGMP-AA (CGMP with
added AAs) versus Phe-free AA, (different protein sources and the same AA composition). The AA
profile was different between group 1 and 2. Measurements were made over 240 min. They reported
no differences in the absorption of total AAs between the two groups, suggesting that CGMP made no
impact on the absorption rate of AAs. However, some individual AAs changed significantly between
the groups. For example, the tyrosine amounts in the different product consumed were markedly
different; group 1, 0.05 g and group 2, 10.81 g. At 30 min post ingestion, plasma tyrosine concentrations
in group 2 were double those in group 1, reflecting changes in the AA profile of the protein substitute
rather than the source of protein.
Gropper et al. [32] and others [33–35] have demonstrated that the type and quality of protein
influences kinetic absorption. Healthy volunteers ingested one of three protein sources: AAs, a mixture
of 75% AA with 25% natural protein, or whole protein. After 150 min, the only AA profile significantly
higher than baseline was the group ingesting whole protein. In the two other groups, peak AA
concentrations were reached before this time point. These studies showed that peak AA concentrations
from a Phe-free AA or Phe-free AA combined with an intact protein source were more rapidly absorbed
compared with an intact protein source only.
Both the time of arrival and pattern of AAs in the systemic circulation are important for effective
protein synthesis. For this to occur efficiently all essential AAs must be presented to the tissues in
appropriate amounts simultaneously. In PKU, the delivery of AAs to tissues is accelerated compared to
a diet based on mixed proteins [12]. Glutamine is the most abundant free AA in the body, with a wide
range of diverse molecular actions [36]. Its primary source is skeletal muscle. Both BCAA and lysine,
by different mechanisms, act as precursors for glutamine synthesis, and leucine can stimulate the release
of glutamine and alanine from muscles. Threonine in high concentrations can decrease glutamine
formation [37]. The importance of understanding the delivery of AAs from protein substitutes and
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their effect on molecular pathways is crucial to long-term health outcomes for patients reliant on
protein substitutes for their main source of nitrogen.
There are limitations to our findings. This was a pilot study with the aim to explore AA absorption
from protein substitutes with different AA compositions. The liquid Phe-free AA preparation
contained 30% more carbohydrate and 50% less fat than the CGMP-AA preparations. Breakfast
provided similar food choices and the protein content was controlled, providing no more than 30% of
their natural/phenylalanine daily allowance; however, we did not standardize the breakfast for all
subjects, nor did we measure the AA concentrations every 30 min or over the course of 240 min as
recommended by others [11,37], thereby missing the peak and baseline values. Similarly, we did not
collect any other supporting data such as insulin and glucose concentrations to review the effect of
insulinotropic AAs between the different protein sources. Our AA analysis did not measure tryptophan.
We did not compare children with PKU with a control group taking a standard breakfast only without
protein substitute.
6. Conclusions
In conclusion, the delivery, timing, and ratios of AAs are essential to maximize nitrogen utilization
and biochemical functions. This pilot investigation compared three protein substitutes with different
AA compositions and two different protein sources. It appeared that the AA composition rather than
protein source was more important in determining postprandial plasma AAs. Further detailed work is
needed to understand the kinetic and functional roles of protein substitute based on different protein
sources and their metabolic impact
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